Comparison of mechanism, pulsatility, and research applications
The PANTHEON trial, a large double-blind RCT in GOLD defined COPD patients with severe airflow obstruction and a history of 2 COPD exacerbations in the previous year, found that NAC 600 mg BID reduced exacerbation rates in NAC group (497 acute exacerbations in 482 patients, 1.16 AcEx/pt/yr) versus placebo (641 acute exacerbations in 482 patients, 1.49 AcEx/Pt/yr), p 1 log 10 ) compared to untreated controls (67)
In the case of viral infections or vectors, this could result in an increase in viral reservoirs due to a defective immune control (104, 121, 122)
More clinical trials in humans are needed to properly evaluate the reproductive effects of these drugs
Without an experienced healthcare provider monitoring your treatment and adjusting the dose, you may not recognize these adverse effects or know how to respond appropriately